■化脓性汗腺炎(HS)患者可能会增加COVID-19感染和药物并发症的风险和合并症。对于HS患者使用COVID-19疫苗的建议,缺乏专家共识。在这里,我们旨在就HS患者的COVID-19疫苗接种提供专家驱动的共识建议.
■由7名皮肤科医生HS专家组成的核心委员会开发的一项改良的Delphi共识调查,包括4个人口统计问题和12个实践陈述,已分发给美国HS基金会赞助的提供商listserv。参与者是主治医师HS专家。调查结果由核心小组审查,并修订和重新提交,直到达成共识(≥70%同意)。
■在33名调查参与者中,有30名(87%)皮肤科医生,1名普通外科医生,1名整形外科医生,和一个风湿病专家。在第一轮之后,关于疫苗咨询和HS治疗咨询的所有12项声明达成了共识。
■现在,这一共识可以作为临床医生与HS患者讨论COVID-19疫苗接种的资源.随着关于COVID-19的新证据的出现,这些建议将需要更新。
UNASSIGNED: Hidradenitis suppurativa (HS) patients may be at increased risk of COVID-19 infection and complications from their medications and comorbidities. There is a lack of expert
consensus on recommendations for the COVID-19 vaccine for HS patients. Herein, we aim to provide expert-driven
consensus recommendations regarding COVID-19 vaccinations in HS patients.
UNASSIGNED: A modified Delphi
consensus survey developed by a core committee of 7 dermatologist HS experts consisting of 4 demographic questions and 12 practice statements was distributed to the US HS Foundation-sponsored provider listserv. Participants were attending physician HS experts. Survey results were to be reviewed by the core group and revised and resubmitted until
consensus (≥70% agreement) was achieved.
UNASSIGNED: Among the 33 survey participants, there were 30 (87%) dermatologists, 1 general surgeon, 1 plastic surgeon, and 1 rheumatologist.
Consensus for all 12 statements on vaccine counseling and HS treatment counseling was achieved after the first round.
UNASSIGNED: For now, this consensus can serve as a resource for clinicians discussing COVID-19 vaccination with their HS patients. These recommendations will need to be updated as new evidence on COVID-19 emerges.